TCW Group Inc. Has $2.61 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

TCW Group Inc. increased its position in shares of Abbott Laboratories (NYSE:ABT) by 2.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,103 shares of the healthcare product maker’s stock after buying an additional 719 shares during the quarter. TCW Group Inc.’s holdings in Abbott Laboratories were worth $2,608,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Signature Resources Capital Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $29,000. Transcendent Capital Group LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at $29,000. Richardson Financial Services Inc. acquired a new position in Abbott Laboratories during the fourth quarter worth $29,000. Redmont Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at $30,000. Finally, True Wealth Design LLC grew its holdings in shares of Abbott Laboratories by 1,677.8% during the fourth quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock valued at $35,000 after buying an additional 302 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ABT. Edward Jones lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, July 30th. Evercore ISI lowered their price objective on Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Raymond James reaffirmed a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Barclays increased their price target on Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Finally, Citigroup cut their price objective on shares of Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating on the stock in a report on Wednesday, May 22nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $121.00.

Abbott Laboratories Trading Up 0.1 %

Shares of Abbott Laboratories stock opened at $111.00 on Monday. The firm has a market cap of $193.10 billion, a PE ratio of 34.58, a P/E/G ratio of 2.74 and a beta of 0.72. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.68 and a quick ratio of 1.11. The stock has a fifty day moving average price of $105.47 and a 200-day moving average price of $108.73.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. The business had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.37 billion. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.08 earnings per share. Equities research analysts anticipate that Abbott Laboratories will post 4.66 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Monday, July 15th were paid a $0.55 dividend. The ex-dividend date was Monday, July 15th. This represents a $2.20 annualized dividend and a yield of 1.98%. Abbott Laboratories’s payout ratio is 68.54%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.